A wearable device that can alert patients and caregivers minutes before a seizure occurs is set to launch across Europe, the UK and other markets, offering people with epilepsy crucial time to reach safety and prevent injuries.
Early seizure alerts
The AI-powered earpiece, developed by Neuraxpharm and Spanish start-up mjn-neuro, continuously records brain activity and uses advanced algorithms to predict when a seizure is about to occur. The device connects to a dedicated mobile app that displays real-time risk information and sends notifications when seizure risk levels rise, marking a major advance in epilepsy care.
Epilepsy affects more than 50 million people globally, with seizures often unpredictable and potentially dangerous. The technology is intended for people with drug-resistant epilepsy, providing proactive warnings that help reduce accidents and improve autonomy. It also supports patients and caregivers with continuous monitoring outside clinical settings.
“At Neuraxpharm, we are dedicated to improving the lives of people with CNS disorders through continuous innovation and strong partnerships. With this launch, we are taking another important step in our journey to improve the daily lives of people with epilepsy,” said Dr Jörg-Thomas Dierks, CEO, Neuraxpharm. He added that combining therapeutic expertise with digital tools will help make “holistic CNS care a reality”.
Trials and launch date
The earpiece sensor, certified in Europe as a Class IIa medical device (CE mark) and also holding UKCA approval, is the first digital health solution designed for real-time early detection of seizures suitable for both ambulatory and homecare use. A multicentre clinical study is currently underway across Spain, the UK and Germany, with interim data being prepared for publication.
David Blánquez, CEO and Co-Founder, mjn-neuro, said the forthcoming European launch is the culmination of more than a decade of development: “Our team has been developing this pioneering project for more than ten years, and thanks to the results obtained from several clinical studies, mjn-neuro has successfully demonstrated solid clinical evidence supporting its effectiveness.”
According to the press release, the launch is scheduled for the second half of 2026.
